Skip to main content
| News

BioFi AG newly settles in Basel

15.08.2022

BioFi has set up its headquarters in Basel. The company has emerged from Crowley Davis Research, which was established in the US state of Idaho in 2000. Using its proprietary technologies, BioFi operates the CellSim platform, which can be used to model and simulate living organisms.

biotechnology

The newly established company BioFi AG has settled in Basel. It brings with it the technological heritage of US company Crowley Davis Research Inc, which is being dissolved, and operates a proprietary, trademarked platform called CellSim. This provides virtual modeling and simulation solutions for living organisms, ranging from single-cell organisms to advanced cancer tissue. The application areas include drug discovery and development and synthetic biology.

Intersection of biology and computer science

Bill Crowley, CEO of Crowley Davis Research and CFO of BioFi AG, commented: “The Basel Area is now home for this collection of proprietary technologies and quite fittingly so; the area is ground zero for exactly the kinds of talent and resources the company needs to achieve its highest and best use in science.” CEO of BioFi AG Thomas Nirnberger adds: “As one of the leading life sciences and technology clusters in Europe, the Basel Area is a natural location to grow a business at the intersection of biology and computer science.”

BioFi’s settlement has been supported by the location and innovation promotion agency Basel Area Business & Innovation and Switzerland Innovation.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation, Invest, Sustainability

KUORI developing biodegradable plastics

The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Cell and gene therapies gain momentum in Basel

Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...

Read More
BLKB expanding support for startups
Basel Area Business & Innovation, Innovation, Invest

BLKB expanding support for startups

BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...

Read More
Combatting the rise of antimicrobial resistance
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Combatting the rise of antimicrobial resistance

Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

AMR Action Fund invests in new antibiotics developed by BioVersys

The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Investors give Resistell 8.5 million Swiss francs

Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology...

Read More
1 2 3 60

Do you have a question? We'd like to hear from you.